| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Catheterization | 15 | 2019 | 298 | 4.590 |
Why?
|
| Heart-Assist Devices | 11 | 2018 | 751 | 2.960 |
Why?
|
| Shock, Cardiogenic | 6 | 2024 | 104 | 2.730 |
Why?
|
| Heart Arrest | 13 | 2018 | 268 | 2.200 |
Why?
|
| Aortic Valve Insufficiency | 5 | 2017 | 131 | 2.150 |
Why?
|
| Septal Occluder Device | 11 | 2020 | 42 | 2.120 |
Why?
|
| Ventricular Fibrillation | 10 | 2016 | 66 | 1.960 |
Why?
|
| Myocardial Infarction | 9 | 2024 | 372 | 1.930 |
Why?
|
| Cardiopulmonary Resuscitation | 9 | 2019 | 192 | 1.880 |
Why?
|
| Myocardial Ischemia | 7 | 2024 | 161 | 1.860 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2023 | 173 | 1.660 |
Why?
|
| Coronary Vessels | 8 | 2024 | 190 | 1.570 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2019 | 177 | 1.570 |
Why?
|
| Echocardiography, Transesophageal | 11 | 2020 | 346 | 1.560 |
Why?
|
| Heart Septal Defects, Ventricular | 3 | 2019 | 69 | 1.530 |
Why?
|
| Ventricular Function, Left | 7 | 2021 | 602 | 1.500 |
Why?
|
| Coronary Angiography | 15 | 2024 | 238 | 1.480 |
Why?
|
| Popliteal Artery | 2 | 2020 | 28 | 1.440 |
Why?
|
| Heart Failure | 9 | 2021 | 1169 | 1.430 |
Why?
|
| Absorbable Implants | 2 | 2020 | 34 | 1.420 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 96 | 1.380 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 92 | 1.310 |
Why?
|
| Treatment Outcome | 35 | 2024 | 8125 | 1.290 |
Why?
|
| Ischemia | 2 | 2020 | 251 | 1.240 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2019 | 473 | 1.090 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2020 | 62 | 1.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 8 | 2012 | 66 | 1.040 |
Why?
|
| Aortic Valve | 4 | 2023 | 239 | 1.040 |
Why?
|
| Endothelin-1 | 3 | 2011 | 40 | 1.040 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 4 | 2020 | 68 | 1.020 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 141 | 0.990 |
Why?
|
| Ultrasonography, Interventional | 3 | 2023 | 123 | 0.970 |
Why?
|
| Coronary Artery Disease | 6 | 2024 | 358 | 0.970 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 79 | 0.900 |
Why?
|
| Male | 54 | 2024 | 41840 | 0.880 |
Why?
|
| Hemodynamics | 6 | 2024 | 726 | 0.880 |
Why?
|
| Prosthesis Design | 7 | 2019 | 291 | 0.840 |
Why?
|
| Pulmonary Embolism | 6 | 2021 | 228 | 0.820 |
Why?
|
| Echocardiography, Three-Dimensional | 6 | 2020 | 516 | 0.820 |
Why?
|
| Endovascular Procedures | 2 | 2017 | 257 | 0.800 |
Why?
|
| Thrombolytic Therapy | 5 | 2021 | 226 | 0.790 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2017 | 195 | 0.780 |
Why?
|
| Humans | 69 | 2024 | 88286 | 0.770 |
Why?
|
| Middle Aged | 29 | 2024 | 25571 | 0.760 |
Why?
|
| Catheterization | 4 | 2017 | 238 | 0.750 |
Why?
|
| Stents | 4 | 2012 | 390 | 0.750 |
Why?
|
| Aged | 28 | 2024 | 18834 | 0.720 |
Why?
|
| Registries | 5 | 2020 | 750 | 0.660 |
Why?
|
| Retrospective Studies | 21 | 2023 | 8836 | 0.640 |
Why?
|
| Hospital Costs | 1 | 2019 | 107 | 0.620 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 30 | 0.610 |
Why?
|
| Coronary Artery Bypass | 3 | 2023 | 232 | 0.610 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 60 | 0.610 |
Why?
|
| Female | 38 | 2024 | 45560 | 0.600 |
Why?
|
| Clinical Protocols | 1 | 2018 | 157 | 0.600 |
Why?
|
| Balloon Occlusion | 3 | 2012 | 29 | 0.600 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 135 | 0.600 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2018 | 41 | 0.600 |
Why?
|
| Arteriovenous Fistula | 1 | 2018 | 53 | 0.590 |
Why?
|
| Blood Circulation | 1 | 2017 | 30 | 0.590 |
Why?
|
| Heart Ventricles | 2 | 2020 | 778 | 0.590 |
Why?
|
| Heart Massage | 1 | 2017 | 12 | 0.590 |
Why?
|
| Venae Cavae | 1 | 2017 | 14 | 0.590 |
Why?
|
| Transposition of Great Vessels | 1 | 2017 | 23 | 0.590 |
Why?
|
| Swine | 13 | 2016 | 578 | 0.580 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 126 | 0.580 |
Why?
|
| Aminophylline | 1 | 2016 | 14 | 0.580 |
Why?
|
| Bradycardia | 1 | 2016 | 39 | 0.570 |
Why?
|
| Device Removal | 1 | 2018 | 167 | 0.570 |
Why?
|
| Heart Septal Defects | 1 | 2016 | 32 | 0.560 |
Why?
|
| Fibrinolytic Agents | 3 | 2021 | 209 | 0.560 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 114 | 0.550 |
Why?
|
| Cardiomyopathies | 2 | 2018 | 260 | 0.550 |
Why?
|
| Dyspnea | 1 | 2016 | 75 | 0.550 |
Why?
|
| Constriction, Pathologic | 1 | 2017 | 217 | 0.550 |
Why?
|
| Balloon Valvuloplasty | 1 | 2015 | 8 | 0.540 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 27 | 0.540 |
Why?
|
| Postoperative Complications | 3 | 2017 | 2272 | 0.530 |
Why?
|
| Disease Management | 1 | 2018 | 328 | 0.530 |
Why?
|
| Vascular Fistula | 1 | 2015 | 12 | 0.530 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 98 | 0.520 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 140 | 0.510 |
Why?
|
| Fontan Procedure | 1 | 2015 | 55 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1034 | 0.500 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2020 | 136 | 0.500 |
Why?
|
| Ventricular Septum | 1 | 2014 | 13 | 0.490 |
Why?
|
| Heart Injuries | 1 | 2014 | 17 | 0.490 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 88 | 0.490 |
Why?
|
| Electrocardiography | 4 | 2012 | 495 | 0.480 |
Why?
|
| Epinephrine | 2 | 2011 | 86 | 0.480 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 69 | 0.480 |
Why?
|
| Adenosine | 1 | 2016 | 238 | 0.470 |
Why?
|
| Time Factors | 10 | 2021 | 5299 | 0.460 |
Why?
|
| Aneurysm, False | 1 | 2014 | 55 | 0.460 |
Why?
|
| Echocardiography, Doppler, Color | 4 | 2015 | 103 | 0.450 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2014 | 87 | 0.430 |
Why?
|
| Risk Assessment | 8 | 2020 | 2281 | 0.420 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 255 | 0.420 |
Why?
|
| Foramen Ovale, Patent | 1 | 2012 | 18 | 0.420 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 364 | 0.410 |
Why?
|
| Biomarkers | 3 | 2019 | 1753 | 0.400 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2013 | 166 | 0.390 |
Why?
|
| Thymosin | 1 | 2011 | 6 | 0.390 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 6687 | 0.390 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 16 | 0.380 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 74 | 0.380 |
Why?
|
| Electric Countershock | 2 | 2011 | 51 | 0.380 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 48 | 0.380 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 159 | 0.360 |
Why?
|
| Coronary Disease | 2 | 2012 | 261 | 0.360 |
Why?
|
| Vascular Patency | 2 | 2020 | 126 | 0.350 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 188 | 0.350 |
Why?
|
| Disease Models, Animal | 10 | 2016 | 2331 | 0.340 |
Why?
|
| Mitral Valve | 3 | 2020 | 258 | 0.340 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 230 | 0.340 |
Why?
|
| After-Hours Care | 1 | 2008 | 8 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 421 | 0.330 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1837 | 0.320 |
Why?
|
| Coronary Thrombosis | 1 | 2008 | 14 | 0.310 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 11 | 0.300 |
Why?
|
| Medical Errors | 1 | 2008 | 116 | 0.300 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2020 | 191 | 0.300 |
Why?
|
| Coronary Circulation | 3 | 2024 | 131 | 0.300 |
Why?
|
| Hypoxia | 1 | 2012 | 650 | 0.290 |
Why?
|
| United States | 7 | 2020 | 6857 | 0.290 |
Why?
|
| Risk Factors | 8 | 2021 | 5430 | 0.290 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3655 | 0.280 |
Why?
|
| Thrombectomy | 1 | 2008 | 168 | 0.280 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 1703 | 0.270 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 301 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 224 | 0.260 |
Why?
|
| Artifacts | 1 | 2007 | 244 | 0.260 |
Why?
|
| Adult | 11 | 2024 | 26230 | 0.260 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 414 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2008 | 379 | 0.250 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2015 | 78 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 454 | 0.240 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2004 | 61 | 0.240 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 333 | 0.240 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 93 | 0.240 |
Why?
|
| Heart Transplantation | 2 | 2023 | 720 | 0.230 |
Why?
|
| Cysteine | 1 | 2024 | 136 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2016 | 297 | 0.220 |
Why?
|
| Clinical Competence | 1 | 2008 | 779 | 0.220 |
Why?
|
| Microcirculation | 2 | 2024 | 106 | 0.210 |
Why?
|
| Ulnar Artery | 1 | 2022 | 5 | 0.210 |
Why?
|
| Survival Rate | 5 | 2019 | 1881 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 1398 | 0.210 |
Why?
|
| Radial Artery | 1 | 2022 | 33 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2013 | 699 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 703 | 0.200 |
Why?
|
| Stroke Volume | 3 | 2021 | 460 | 0.200 |
Why?
|
| Aorta | 2 | 2020 | 286 | 0.200 |
Why?
|
| Pilot Projects | 1 | 2024 | 860 | 0.190 |
Why?
|
| Acute Disease | 3 | 2021 | 838 | 0.190 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1972 | 0.190 |
Why?
|
| Transillumination | 1 | 2020 | 9 | 0.190 |
Why?
|
| Limb Salvage | 1 | 2020 | 33 | 0.180 |
Why?
|
| Ultrasonography | 3 | 2015 | 703 | 0.180 |
Why?
|
| Reoperation | 2 | 2013 | 606 | 0.180 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 12 | 0.180 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2011 | 83 | 0.180 |
Why?
|
| Recovery of Function | 2 | 2018 | 289 | 0.170 |
Why?
|
| Resuscitation | 2 | 2011 | 105 | 0.170 |
Why?
|
| Animals | 14 | 2016 | 27127 | 0.170 |
Why?
|
| Coronary Restenosis | 3 | 2010 | 11 | 0.170 |
Why?
|
| Fluoroscopy | 1 | 2019 | 122 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 250 | 0.160 |
Why?
|
| Saphenous Vein | 2 | 2010 | 61 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 137 | 0.160 |
Why?
|
| Monocytes | 1 | 2019 | 217 | 0.160 |
Why?
|
| Microvessels | 1 | 2018 | 70 | 0.150 |
Why?
|
| Echocardiography | 4 | 2020 | 933 | 0.150 |
Why?
|
| Recurrence | 2 | 2012 | 1170 | 0.150 |
Why?
|
| Arterial Switch Operation | 1 | 2017 | 5 | 0.150 |
Why?
|
| Triage | 1 | 2018 | 111 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 278 | 0.150 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2016 | 6 | 0.150 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2016 | 6 | 0.150 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 243 | 0.150 |
Why?
|
| Renal Veins | 1 | 2017 | 28 | 0.140 |
Why?
|
| Tumor Necrosis Factors | 1 | 2016 | 14 | 0.140 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 148 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 38 | 0.140 |
Why?
|
| Bioprosthesis | 1 | 2016 | 37 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2017 | 51 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 165 | 0.140 |
Why?
|
| Emergency Service, Hospital | 3 | 2016 | 508 | 0.140 |
Why?
|
| Heart Atria | 2 | 2016 | 281 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2019 | 946 | 0.140 |
Why?
|
| Macrophages | 1 | 2019 | 572 | 0.130 |
Why?
|
| Cannula | 1 | 2016 | 50 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2016 | 120 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2019 | 846 | 0.130 |
Why?
|
| Subclavian Artery | 1 | 2015 | 43 | 0.130 |
Why?
|
| Length of Stay | 1 | 2019 | 722 | 0.130 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 97 | 0.130 |
Why?
|
| Prognosis | 3 | 2020 | 3740 | 0.130 |
Why?
|
| Atrial Appendage | 1 | 2015 | 29 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 306 | 0.120 |
Why?
|
| Random Allocation | 4 | 2020 | 329 | 0.120 |
Why?
|
| Comorbidity | 2 | 2015 | 943 | 0.120 |
Why?
|
| Hyperthermia, Induced | 1 | 2014 | 73 | 0.120 |
Why?
|
| Aortography | 1 | 2014 | 64 | 0.120 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2013 | 16 | 0.120 |
Why?
|
| Infusions, Parenteral | 1 | 2013 | 51 | 0.110 |
Why?
|
| Amiodarone | 1 | 2013 | 13 | 0.110 |
Why?
|
| Contrast Media | 1 | 2018 | 1084 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 3426 | 0.110 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2013 | 71 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 2629 | 0.110 |
Why?
|
| International Normalized Ratio | 1 | 2013 | 39 | 0.110 |
Why?
|
| Dobutamine | 1 | 2013 | 61 | 0.110 |
Why?
|
| Kidney | 1 | 2018 | 1145 | 0.110 |
Why?
|
| Thrombosis | 1 | 2016 | 301 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 2742 | 0.110 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 50 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2013 | 63 | 0.110 |
Why?
|
| Software | 1 | 2017 | 661 | 0.110 |
Why?
|
| Heart | 2 | 2020 | 572 | 0.110 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2013 | 111 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2015 | 251 | 0.110 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2012 | 7 | 0.100 |
Why?
|
| Exercise Test | 1 | 2013 | 164 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2014 | 283 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 681 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1542 | 0.100 |
Why?
|
| Mitral Valve Stenosis | 1 | 2012 | 38 | 0.100 |
Why?
|
| Labetalol | 1 | 2011 | 6 | 0.100 |
Why?
|
| Metoprolol | 1 | 2011 | 15 | 0.100 |
Why?
|
| Vascular Resistance | 2 | 2024 | 102 | 0.100 |
Why?
|
| Radiography, Interventional | 1 | 2012 | 154 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 104 | 0.100 |
Why?
|
| Catheters | 2 | 2021 | 76 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 836 | 0.100 |
Why?
|
| California | 2 | 2010 | 143 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 144 | 0.090 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 25 | 0.090 |
Why?
|
| Infliximab | 4 | 2013 | 153 | 0.090 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 466 | 0.090 |
Why?
|
| Vasopressins | 1 | 2010 | 49 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 242 | 0.090 |
Why?
|
| Drug-Eluting Stents | 1 | 2010 | 16 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 345 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 266 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 102 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2013 | 885 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2010 | 99 | 0.090 |
Why?
|
| Critical Illness | 1 | 2012 | 304 | 0.090 |
Why?
|
| Sirolimus | 1 | 2010 | 172 | 0.080 |
Why?
|
| Endothelin-2 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Endothelin-3 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Ventricular Premature Complexes | 1 | 2008 | 8 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2010 | 350 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2010 | 477 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 139 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 351 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2019 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 729 | 0.080 |
Why?
|
| Chicago | 1 | 2013 | 1404 | 0.080 |
Why?
|
| Heart Rate | 1 | 2010 | 492 | 0.080 |
Why?
|
| Fatigue | 1 | 2008 | 178 | 0.080 |
Why?
|
| Workload | 1 | 2008 | 129 | 0.080 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 93 | 0.080 |
Why?
|
| Selection Bias | 1 | 2007 | 37 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 783 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2008 | 137 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2008 | 226 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2005 | 30 | 0.070 |
Why?
|
| Cytokines | 1 | 2009 | 801 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 39 | 0.070 |
Why?
|
| Observer Variation | 1 | 2007 | 607 | 0.060 |
Why?
|
| Metals | 1 | 2005 | 91 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 993 | 0.060 |
Why?
|
| Action Potentials | 1 | 2008 | 590 | 0.060 |
Why?
|
| Patient Selection | 2 | 2020 | 686 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1511 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 524 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 642 | 0.060 |
Why?
|
| Caspases | 1 | 2003 | 156 | 0.060 |
Why?
|
| Young Adult | 1 | 2015 | 6171 | 0.060 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2005 | 222 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 241 | 0.050 |
Why?
|
| Spasm | 1 | 2022 | 17 | 0.050 |
Why?
|
| Preoperative Care | 2 | 2015 | 399 | 0.050 |
Why?
|
| Ventricular Pressure | 1 | 2021 | 37 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1846 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 87 | 0.050 |
Why?
|
| Pulmonary Valve | 1 | 2020 | 34 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2020 | 156 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 494 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 4257 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 367 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1245 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 275 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 23 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 381 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 298 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 684 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2021 | 423 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2019 | 463 | 0.040 |
Why?
|
| Equipment Design | 1 | 2018 | 415 | 0.040 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 16 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 342 | 0.040 |
Why?
|
| Apoptosis | 1 | 2003 | 1713 | 0.040 |
Why?
|
| Phlebography | 1 | 2017 | 66 | 0.040 |
Why?
|
| Illinois | 1 | 2018 | 465 | 0.030 |
Why?
|
| Quality of Life | 1 | 2004 | 1646 | 0.030 |
Why?
|
| Oxygen | 1 | 2021 | 743 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 367 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 295 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 281 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 222 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 302 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2013 | 13 | 0.030 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2013 | 6 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2013 | 20 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 566 | 0.030 |
Why?
|
| Lidocaine | 1 | 2013 | 64 | 0.030 |
Why?
|
| Etanercept | 1 | 2013 | 33 | 0.030 |
Why?
|
| Heart Arrest, Induced | 1 | 2013 | 31 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2013 | 189 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 90 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 2013 | 95 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2013 | 153 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2013 | 144 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 665 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2011 | 50 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 226 | 0.020 |
Why?
|
| Adrenergic Antagonists | 1 | 2010 | 3 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 307 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 597 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 78 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 360 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 155 | 0.020 |
Why?
|
| Cardiology Service, Hospital | 1 | 2008 | 4 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1857 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 276 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1855 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 222 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 857 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 957 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1060 | 0.020 |
Why?
|
| Dilatation, Pathologic | 1 | 2006 | 55 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2008 | 210 | 0.020 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2003 | 25 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 33 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 901 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2003 | 60 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2003 | 151 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 640 | 0.010 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2006 | 468 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1587 | 0.010 |
Why?
|